WEKO3
アイテム
Antithrombin improves the maternal and neonatal outcomes but not the angiogenic factors in extremely growth-restricted fetuses at <28 weeks of gestation
http://hdl.handle.net/10458/0002000453
http://hdl.handle.net/10458/0002000453f4eea60a-7dcc-4a9b-83b1-9879f97259e4
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2024-01-26 | |||||
| タイトル | ||||||
| タイトル | Antithrombin improves the maternal and neonatal outcomes but not the angiogenic factors in extremely growth-restricted fetuses at <28 weeks of gestation | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| キーワード | Antithrombin | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| キーワード | fetal growth restriction | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| キーワード | placental pathology | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| キーワード | perinatal mortality | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| キーワード | preeclampsia | |||||
| 資源タイプ | ||||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| 著者 |
藤﨑, 碧
× 藤﨑, 碧× 古田, 賢× 大橋, 昌尚× 古川, 誠志× 児玉, 由紀× 川越, 靖之× 鮫島, 浩× 池ノ上, 克 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Aims: Severe preterm fetal growth restriction (FGR) remote from term is problematic. We aimed to investigate the effect of maternally-administered antithrombin on maternal and neonatal outcomes. A prospective, one-arm, pilot study was performed in 14 women with severe FGR (≤5th centile) at <28 weeks of gestation, without hypertensive disorders. Maternal plasma concentrations of soluble Feline McDonough Sarcoma (FMS)-like trypsin kinase-1 (sFlt-1) and placental growth factor (PlGF) were measured and categorized into three groups: group 1; low sFlt-1 and high PlGF, group 2; moderate sFlt-1 and low PlGF, and group 3; high sFlt-1 and low PlGF. Antithrombin was administered for 3 days. The incidence of perinatal mortality, infant morbidity, and the period of pregnancy prolongation were compared. Results: In group 1 (n=4), their pregnancies were extended for longer periods and the maternal and infant outcomes were good. The prolongation periods were shorter in groups 2 (n=3) and 3 (n=7), which resulted in poor maternal [severe preeclampsia or hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome] and infant outcomes. Conclusions: The evaluation of the maternal sFlt-1 and PlGF at 21–27 weeks of gestation is useful in the managements of severe FGR. Antithrombin treatment could prolong the pregnancies with low sFlt-1 and high PlGF without negatively affecting maternal or fetal health. |
|||||
| 言語 | en | |||||
| 内容記述 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Citation: Fujisaki M, Furuta K, Ohhashi M, Furukawa S, Kodama Y, Kawagoe Y, Sameshima H, Ikenoue T. Antithrombin improves the maternal and neonatal outcomes but not the angiogenic factors in extremely growth-restricted fetuses at <28 weeks of gestation. J Perinat Med. 2017 Oct 26;45(7):837-842. doi: 10.1515/jpm-2016-0190. PMID: 27914214. |
|||||
| 言語 | en | |||||
| 書誌情報 |
en : Journal of Perinatal Medicine 巻 45, 号 7, p. 837-842, 発行日 2016-12-03 |
|||||
| 出版者 | ||||||
| 出版者 | Walter de Gruyter | |||||
| 言語 | en | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0300-5577 | |||||
| DOI | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | https://doi.org/10.1515/jpm-2016-0190 | |||||
| 権利 | ||||||
| 言語 | en | |||||
| 著者版フラグ | ||||||
| 出版タイプ | NA | |||||
